Ignite Creation Date:
2024-05-05 @ 11:14 PM
Last Modification Date:
2024-10-26 @ 10:30 AM
Study NCT ID:
NCT01286675
Status:
COMPLETED
Last Update Posted:
2019-03-01
First Post:
2011-01-28
Brief Title:
Effect of Eltrombopag Plus G-CSF on Human CD34 Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34 Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Eltrombopag may improve the cell collection available for Autologous Stem Cell TransplantASCT The overall goal is to determine if adding Eltrombopag to the standard ASCT will increase the number of blood cells collected and reduce the number of times blood needs to be collected This study will also determine the highest dose of Eltrombopag that can be used without causing serious side effects
Detailed Description:
Subjects will receive standard treatment for autologous stem cell transplant Subjects will be assigned to receive no Eltrombopag or one of three dose levels of Eltrombopag Subjects will receive oral Eltrombopag on days 2-15 of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None